Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-label, Single-dose Phase 1 Clinical Study to Investigate the Absorption, Metabolism and Excretion of APG-2575 in Healthy Subjects After Oral Administration of 400 mg/200 µCi [14C] APG-2575 Solution

NCT05517616 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT05517616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05517616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-label, Single-dose Phase 1 Clinical Study to Investigate the Absorption, Metabolism and Excretion of APG-2575 in Healthy Subjects After Oral Administration of 400 mg/200 µCi [14C] APG-2575 Solution
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 14, 2022
Completion date
April 20, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics